Ultromics
Ultromics develops AI-powered echocardiography analysis software that detects complex cardiac diseases including HFpEF and cardiac amyloidosis, serving U.S. and U.K. hospitals and health systems with FDA-cleared, Medicare-reimbursable diagnostic tools integrated into PACS workflows.
- Company typePrivate
- Founded2017
- HeadquartersOxford, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Ultromics does
Ultromics is a University of Oxford spin-out (founded 2017 by Dr. Ross Upton and Prof. Paul Leeson) that builds AI-powered software for analyzing routine echocardiograms to detect complex cardiovascular disease. The company's flagship platform, EchoGo, applies 3D convolutional neural networks trained on more than 10 years of outcome-annotated clinical data to deliver automated diagnostic reports within roughly 20 minutes via DICOM workflow integration with hospital PACS systems. The platform powers three FDA-cleared medical devices: EchoGo Heart Failure (the first and only FDA-cleared diagnostic support tool for HFpEF detection, with 90% sensitivity and 86% specificity), EchoGo Amyloidosis (the first FDA-cleared AI tool for cardiac amyloidosis detection, with Breakthrough Device Designation and 85% sensitivity / 93% specificity), and EchoGo Core (automated EF, GLS, and volume quantification with zero inter-observer variability). The company is based in Oxford, UK with a U.S. subsidiary in Atlanta and commercial leadership in Dallas.
Ultromics monetizes primarily through a per-analysis revenue model: EchoGo Heart Failure is reimbursable under Medicare CPT code 0932T at $316 per analysis in outpatient settings, with inpatient reimbursement following DRG methodology. The company supplements per-analysis revenue with enterprise licensing agreements with major health systems and operates a self-serve trial option and a Microsoft Azure Marketplace listing. To date, EchoGo has processed more than 430,000 clinical cases across hospitals in the U.S. and U.K., supported by 50+ peer-reviewed publications and clinical validation partnerships with Mayo Clinic, Cleveland Clinic, Northwestern Medicine, Beth Israel Deaconess, MedStar Health, NHS UK, and the Foundation for the National Institutes of Health. Go-to-market is enterprise field sales, complemented by pharma co-development partnerships with Johnson & Johnson Innovative Medicine and Pfizer on the EchoGo Amyloidosis program.
The company has raised approximately $110 million+ in venture funding across multiple rounds, including a $33 million Series B (2021, led by Blue Venture Fund with Optum Ventures and GV) and a $55 million Series C (July 2025, co-led by L&G, Allegis Capital, and Lightrock), plus a strategic investment from the American Heart Association's Go Red for Women Venture Fund in December 2025. Investors also include Oxford Science Enterprises, UCM Ventures, and Nina Capital. Customers are large academic medical centers and integrated delivery networks in the U.S. and U.K., and the company is actively scaling U.S. commercial operations following Medicare reimbursement and the 2024 FDA clearance of EchoGo Amyloidosis.
Ultromics firmographics
Firmographics- Name
- Ultromics
- Legal name
- Ultromics Limited
- Website
- https://ultromics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Ultromics develops AI-powered echocardiography analysis software that detects complex cardiac diseases including HFpEF and cardiac amyloidosis, serving U.S. and U.K. hospitals and health systems with FDA-cleared, Medicare-reimbursable diagnostic tools integrated into PACS workflows.
- Ownership category
- akta.pro rank
Ultromics industry classification
Industry- Product category
- AI Cardiac Diagnostics Software
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Ultromics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Ultromics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- EchoGo Heart Failure Analysis: Per-analysis Medicare reimbursement for AI cardiac diagnostics. CPT code 0932T provides $316 per analysis for outpatient settings, with DRG payment methodology for inpatient.
- SaaS Platform Services: Cloud-based AI diagnostic platform that processes echocardiograms and delivers automated DICOM reports to PACS systems. Revenue generated per analysis and through enterprise licensing agreements with healthcare systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | CPT code 0932T - EchoGo Heart Failure outpatient analysis |
| Transaction based/ take rate | Pay-as-you-go | Inpatient EchoGo analysis |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Ultromics product offering
Product offeringCore offering
Ultromics develops and sells the EchoGo platform, a cloud-based AI-powered SaaS solution that analyzes routine echocardiogram video clips to detect complex cardiac diseases including heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform powers FDA-cleared medical devices (EchoGo Heart Failure, EchoGo Amyloidosis, and EchoGo Core) that deliver automated structured DICOM reports to PACS systems within 20 minutes, targeting hospitals and healthcare systems in the U.S. and U.K.
Product overview
Ultromics offers the EchoGo platform, a unified AI-powered SaaS solution for cardiovascular disease detection through echocardiography analysis. The platform comprises two FDA-cleared diagnostic modules: EchoGo Heart Failure for detecting heart failure with preserved ejection fraction (HFpEF), and EchoGo Amyloidosis for cardiac amyloidosis screening. Both modules leverage deep learning computer vision models trained on over 10 years of outcome data to analyze routine echocardiogram video clips and deliver automated diagnostic reports within 20 minutes. The platform integrates with existing hospital PACS infrastructure and is reimbursable under CPT code 0932T ($316 per analysis).
Differentiator
Problem solved
Functional benefit
Brands
- EchoGo Heart Failure: FDA-cleared AI-powered diagnostic support tool for detecting heart failure with preserved ejection fraction (HFpEF) from routine echocardiogram analysis.
- EchoGo Amyloidosis
- EchoGo Core
- EchoGo Platform
Products and services
- EchoGo Platform
Quantifiable outcome
- EchoGo Heart Failure achieves 90% sensitivity and 86% specificity for HFpEF detection
- +5 more outcomes
Companies that use Ultromics
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Ultromics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature4 records
Ultromics partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- PfizercoreCo-development partner for EchoGo Amyloidosis device, contributing to FDA Breakthrough Device Designation and marketing authorization through TAP program.
- Johnson & Johnson Innovative MedicinecoreCollaboration to develop EchoGo Amyloidosis AI platform using artificial intelligence to detect cardiac amyloidosis from routine echocardiograms. Platform received FDA Breakthrough Device Status and is prepared for U.S. commercialization.
- Mayo CliniccoreKey clinical validation partner; built EchoGo in collaboration with Mayo Clinic; hosts key opinion leaders including Dr. Patricia Pellikka; contributed to multiple clinical studies.
- NHS UKcoreTechnology built in partnership with NHS for echocardiography analysis; supported by NHS England; deployed across NHS sites.
- FNIH (Foundation for the National Institutes of Health)corePartner in Accelerating Medicines Partnership Heart Failure (AMP HF) 5-year, $37 million multi-stakeholder collaboration to investigate HFpEF.
- American Society of Echocardiography (ASE)coreASE IRT partnership; member and leader of ASE AI taskforce setting principles and guidance for AI in echocardiography.
- University of OxfordcoreSpin-out company founded at Oxford University in 2017; ongoing research partnership with Oxford Cardiovascular Clinical Research Facility.
- Cleveland CliniccoreClinical validation partner; conducted utility study of EchoGo for COVID-19 risk stratification.
- MedStar HealthcoreWASE-COVID study partner; Director Dr. Federico Asch served as principal investigator.
- Northwestern MedicinecoreEchoGo HFpEF clinical deployment partner; published initial experience study with Dr. Akhil Narang.
- Microsoft AzurecoreCloud infrastructure provider for EchoGo platform; data centers in UK and North America.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Ultromics competitors and assessment
Company assessmentEmerging players
- Cleerly: Cleerly applies AI to cardiac CT imaging for plaque and ischemia assessment; competes with Ultromics in AI-driven cardiovascular diagnostics but uses a different imaging modality and use case.
- HeartFlow: HeartFlow provides AI-driven cardiac CT FFR analysis for coronary disease; a comparable AI-cardiology-diagnostics peer but focused on CT rather than echocardiography and ischemia rather than HFpEF/amyloidosis.
- Eko Health: Eko Health builds AI-enabled cardiac ultrasound and digital stethoscope devices with embedded AI for cardiac disease detection; competes at the intersection of point-of-care ultrasound and AI diagnostics adjacent to Ultromics' echo AI.
- RapidAI: RapidAI offers AI imaging analysis platforms initially focused on stroke and expanding into other vascular/cardiac conditions; comparable as an AI imaging diagnostics vendor to hospital systems.
- Viz.ai: Viz.ai applies AI to medical imaging workflow across multiple specialties, including cardiology, and competes with Ultromics in AI-powered cardiac imaging analytics and hospital deployment.
Direct peers
- Caption Health (GE HealthCare): Acquired by GE HealthCare in 2023, Caption Health was the leading AI-guided echocardiography acquisition and analysis platform and is the closest direct competitor to Ultromics' EchoGo platform, serving similar cardiology workflows.
- Us2.ai: Us2.ai develops AI software that automates echocardiogram analysis for cardiac function assessment, directly competing with EchoGo Core and EchoGo Heart Failure on AI-driven cardiac measurement and disease detection.
- DiA Imaging Analysis: DiA Imaging Analysis provides AI-based ultrasound image analysis tools, including cardiac applications, that compete with Ultromics' EchoGo Core automated measurement capabilities for echocardiography.
Broad incumbents
- Tempus Labs: Tempus is a large AI-driven precision medicine company with capabilities spanning imaging, pathology, and clinical data; while not a focused echocardiography peer, it competes broadly for AI diagnostics budget and hospital AI partnerships.
- Philips (Cardiology Informatics): Philips operates Intellispace Cardiovascular and cardiology informatics suites sold into the same hospital systems as Ultromics; multiple Ultromics executives came from Philips cardiology informatics, making it the most directly comparable incumbent competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Ultromics social profiles
Digital presenceUltromics compliance and trust
Trust signalCompliance5 records
Ultromics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ultromics leadership team
Management profileNumber of profiles
Profiles9 records
Ultromics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ultromics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ultromics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ultromics
What does Ultromics do?
Ultromics develops and sells the EchoGo platform, a cloud-based AI-powered SaaS solution that analyzes routine echocardiogram video clips to detect complex cardiac diseases including heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform powers FDA-cleared medical devices (EchoGo Heart Failure, EchoGo Amyloidosis, and EchoGo Core) that deliver automated structured DICOM reports to PACS systems within 20 minutes, targeting hospitals and healthcare systems in the U.S. and U.K.
Is Ultromics a public or private company?
Ultromics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ultromics founded?
Ultromics was founded in 2017. It employs 101 to 250 people.
Where is Ultromics based?
Ultromics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Ultromics make money?
Two revenue lines are on record. EchoGo Heart Failure Analysis are the primary driver. The others are saaS Platform Services.
Who are Ultromics's main competitors?
Emerging players on record are Cleerly, HeartFlow, Eko Health, RapidAI and Viz.ai. Direct peers are Caption Health (GE HealthCare), Us2.ai and DiA Imaging Analysis. Broad incumbents are Tempus Labs and Philips (Cardiology Informatics).
Does Ultromics have an API?
No public API is recorded for Ultromics.
What industry is Ultromics in?
Ultromics's product category is AI Cardiac Diagnostics Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA). Its NAICS code is 621511 and its SIC code is 3841.